The Saladax Board of Directors consists of the Company founders and the following individuals:
Joel Gross is a veteran of more than 25 years in the telecommunications industry, having worked as an executive for several small and large firms, across several different disciplines including finance, sales and marketing, regulatory, corporate, and business development. Mr. Gross was a highly ranked Wall Street analyst for seven years. He graduated with honors from Rutgers University with a B.S. in economics and has an M.B.A. with honors from Penn State. He currently is a consultant and investor, and is a guest speaker at several universities.
Kevin Harter is Executive Chairman of Saladax Biomedical, Inc. Harter was previously a co-founder and Senior Vice President of the Life Science Greenhouse, managing a portfolio of early-stage biotech, device, and diagnostic companies. Harter founded Keystone Medical Systems in 1990 and managed it through significant growth until its acquisition by publicly-held Continental Medical Systems. Prior to Keystone, Harter held several positions within the Pennsylvania Blue Shield organization, including Vice President, Technology. Harter contributed to the development of the field of electronic claims, electronic medical records and physician practice management. Harter was also founder or co-founder of several other health-related companies, including ybn.com, and Personal Medical Records, Inc. He has held more than a dozen board seats in technology and financial companies. Recognition for his professional and volunteer achievements includes the Entrepreneur of the Year award and the Philip Mitchell Service Award from the Pennsylvania State University. He holds a B.S. and MBA from the Pennsylvania State University.
James F. Hensel is Senior Vice President at Columbia Ventures Corporation (CVC). Mr. Hensel and CVC are both Series B Preferred Stock investors in Saladax Biomedical. For CVC Mr. Hensel focuses on both domestic and international telecom holdings. Mr. Hensel most recently served as CEO and President of Metro One Telecommunications, Inc. (PK:INFO) and as the DIP Lender to Pac-West Telecomm, Inc, both restructurings. Mr. Hensel is a serial entrepreneur. He started a medical device company, HemCon, Inc. Prior to HemCon, Mr. Hensel built and oversaw the operations of a $315 million aluminum smelter in Iceland for CVC and microbreweries around the western U.S. Mr. Hensel was previously a partner at Ater Wynne, a large law firm in Portland, Oregon. He is a board member of several private and nonprofit companies. Mr. Hensel holds a B.A. from Harvard University and a J.D. from Willamette University College of Law in Salem, Oregon.
Enrico Petrillo, M.D., is Managing Director of Excel Venture Management. He has a wealth of experience as a venture investor, healthcare consultant, entrepreneur, and physician that has been instrumental in the success of CB Health Ventures (CBHV). Dr. Petrillo has been advising and building successful healthcare and IT companies for over 20 years. He initiated investments in Aileron, MedVentive, US Genomics, BioTrove, Quovadx (now Healthvision), eBenX (acquired by SHPS), and Morphotek (acquired by Eisai), as well as Saladax. Dr. Petrillo has been a Director and/or an Observer at GeneOhm (acquired by Becton Dickinson - BDX ), Exact (EXAS) , Aileron Therapeutics, MedVentive, Saladax, BioTrove (acquired by LIFE Technologies - LIFE), U.S. Genomics, Morphotek, Quovadx, eBenX, TransMedics, and was a founder of Molecular Insight (MIPI). Previously he was a partner at Fletcher Spaght, a Boston-based consulting firm spun out of Boston Consulting Group that specializes in strategy and market consulting for multi-stage medical and IT companies. He is a current advisor to the Department of Defense, Office of the Secretary and affiliated agencies. Dr. Petrillo is also an Adjunct Assistant Professor of Medicine at Boston University. Dr. Petrillo earned both his undergraduate and M.D. degrees from Tufts University, and completed his internship and residency at Harvard-affiliated hospitals in Boston.